Product Details
Alternative Name: | Multidrug resistance-associated protein 4, ABCC4 |
|
Clone: | M4I-80 |
|
Host: | Rat |
|
Isotype: | IgG2a |
|
Immunogen: | Recombinant human MRP4 (multidrug resistance-associated protein 4) (aa 372-431). |
|
UniProt ID: | O15439 |
|
Species reactivity: | Human, Mouse
|
|
Applications: | ICC, IHC (FS), WB
|
|
Recommended Dilutions/Conditions: | Immunocytochemistry: Use 1:20-1:50 dilution on acetone fixed cytospin preparations. Immunohistochemistry (frozen sections): Use 1:20 dilution on acetone fixed frozen sections followed by incubation with biotin-labelled rabbit anti-rat IgG and HRP-labelled streptavidin. Western Blot: Use 1:20-1:50 dilution and HRP-anti-rat-IgG. Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
|
Application Notes: | Immunocytochemistry: cytospin preparations |
|
Formulation: | Liquid. In serum free culture supernatant containing 0.7% BSA and 0.1% sodium azide. |
|
Shipping: | Blue Ice |
|
Short Term Storage: | +4°C |
|
Long Term Storage: | -20°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Product Literature References
Optimization of an Oral Mucosa in vitro Model Based on Cell Line TR146: G.C. Lin, et al.; Tissue Barriers
21, 1748459 (2020),
Abstract;
Serum-derived factors of breast cancer patients with brain metastases alter permeability of a human blood–brain barrier model: C.J. Curtaz, et al.; Fluids Barriers CNS
17, 31 (2020),
Abstract;
Full Text
Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis: E.S. Jeong, et al.; Toxicol. Appl. Pharmacol.
288, 213 (2015),
Application(s): Western blot ,
Abstract;
Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo: M.L. Vlaming et al.; Clin. Cancer Res.
15, 3084 (2009),
Abstract;
Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate: M.L. Vlaming et al.; Clin. Cancer Res.
14, 8152 (2008),
Abstract;
Mrp4 confers resistance to topotecan and protects the brain from chemotherapy: M. Leggas, et al.; Mol. Cell. Biol.
24, 7612 (2004),
Abstract;